The durable 36-week response in the highest dose cohort strengthens the case for EP-104GI ahead of Phase 2b top-line data expected in Q4 2026. Traders should monitor for further data disclosures and position ahead of the placebo-controlled readout, which could be a major value inflection point.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained symptom and tissue health improvements in patients with eosinophilic esophagitis (EoE) treated with EP-104GI. The highest dose cohort demonstrated 66% clinical remission and strong biomarker responses, with no drug-related serious adverse events reported.
Key Facts
- Cohort 9 (n=3) showed 90% reduction in EoEHSS Stage and 88% reduction in Grade at 36 weeks
- 72% reduction in Peak Eosinophil Count (PEC) from baseline in Cohort 9
- 66% of patients (2 of 3) maintained clinical remission (≥3-point SDI reduction) from week 8 through 36
- No drug-related serious adverse events (SAEs) across 31 patients and over 230 patient-months of follow-up
- No cases of oropharyngeal candidiasis, glucose derangement, or adrenal insufficiency reported
Financial Impact
Positive catalyst for valuation based on durable efficacy and clean safety profile in a high-dose cohort
Risk Factors
- Small sample size (n=3) in Cohort 9 limits statistical power
- Phase 2b placebo-controlled data may not replicate open-label results
- Forward-looking statements subject to clinical and regulatory uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277764 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers